Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas
Uloženo v:
| Název: | Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas |
|---|---|
| Autoři: | Naureen Keric, Harald Krenzlin, Darius Kalasauskas, Christian F. Freyschlag, Oliver Schnell, Martin Misch, Christian von der Brelie, Jens Gempt, Aleksandrs Krigers, Arthur Wagner, Felipa Lange, Dorothee Mielke, Clemens Sommer, Marc A. Brockmann, Bernhard Meyer, Veit Rohde, Peter Vajkoczy, Jürgen Beck, Claudius Thomé, Florian Ringel |
| Přispěvatelé: | Johannes Gutenberg-Universität Mainz, Keric, Naureen, Krenzlin, Harald, Kalasauskas, Darius, Freyschlag, Christian F., Schnell, Oliver, Misch, Martin, von der Brelie, Christian, Gempt, Jens, Krigers, Aleksandrs, Wagner, Arthur, Ringel, Florian |
| Zdroj: | J Neurooncol |
| Informace o vydavateli: | Springer Science and Business Media LLC, 2024. |
| Rok vydání: | 2024 |
| Témata: | Male, 610 Medizin, Extend of resection, World Health Organization [MeSH], Prognostic factors, IDH1/2 wildtype, Male [MeSH], Astrocytoma/genetics [MeSH], Glioma/therapy [MeSH], Female [MeSH], Mutation [MeSH], Brain Neoplasms/genetics [MeSH], Humans [MeSH], Astrocytoma/pathology [MeSH], Treatment Outcome [MeSH], ErbB Receptors/genetics [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Glioblastoma, Astrocytoma/therapy [MeSH], Glioma/diagnosis [MeSH], WHO grade II or III astrocytomas, Research, Glioma/genetics [MeSH], Prognosis [MeSH], Isocitrate Dehydrogenase/genetics [MeSH], Brain Neoplasms/pathology [MeSH], Brain Neoplasms/therapy [MeSH], Astrocytoma, World Health Organization, 03 medical and health sciences, 0302 clinical medicine, 610 Medical sciences, Humans, Retrospective Studies, ddc:610, Brain Neoplasms, Glioma, Middle Aged, Prognosis, Isocitrate Dehydrogenase, ddc, 3. Good health, ErbB Receptors, Treatment Outcome, Mutation, Female |
| Popis: | Background Isocitrate dehydrogenase (IDH)1/2 wildtype (wt) astrocytomas formerly classified as WHO grade II or III have significantly shorter PFS and OS than IDH mutated WHO grade 2 and 3 gliomas leading to a classification as CNS WHO grade 4. It is the aim of this study to evaluate differences in the treatment-related clinical course of these tumors as they are largely unknown. Methods Patients undergoing surgery (between 2016–2019 in six neurosurgical departments) for a histologically diagnosed WHO grade 2–3 IDH1/2-wt astrocytoma were retrospectively reviewed to assess progression free survival (PFS), overall survival (OS), and prognostic factors. Results This multi-center study included 157 patients (mean age 58 years (20–87 years); with 36.9% females). The predominant histology was anaplastic astrocytoma WHO grade 3 (78.3%), followed by diffuse astrocytoma WHO grade 2 (21.7%). Gross total resection (GTR) was achieved in 37.6%, subtotal resection (STR) in 28.7%, and biopsy was performed in 33.8%. The median PFS (12.5 months) and OS (27.0 months) did not differ between WHO grades. Both, GTR and STR significantly increased PFS (P Conclusions WHO grade 2 and 3 IDH1/2 wt astrocytomas, treated according to the same treatment protocols, have a similar OS. Age, extent of resection, and strong EGFR expression were the most important treatment related prognostic factors. |
| Druh dokumentu: | Article Other literature type |
| Popis souboru: | application/pdf; pdf |
| Jazyk: | English |
| ISSN: | 1573-7373 0167-594X |
| DOI: | 10.1007/s11060-024-04585-7 |
| DOI: | 10.25358/openscience-11033 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/38326661 https://openscience.ub.uni-mainz.de/handle/20.500.12030/11052 https://doi.org/10.25358/openscience-11033 https://resolver.sub.uni-goettingen.de/purl?gro-2/142142 https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/113580 https://doi.org/10.1007/s11060-024-04585-7 https://nbn-resolving.org/urn:nbn:de:bvb:384-opus4-1135805 https://opus.bibliothek.uni-augsburg.de/opus4/files/113580/113580.pdf https://repository.publisso.de/resource/frl:6513570 https://mediatum.ub.tum.de/1770659 |
| Rights: | CC BY |
| Přístupové číslo: | edsair.doi.dedup.....5762abf71dce6c9fa91252fcb71f61dd |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Background Isocitrate dehydrogenase (IDH)1/2 wildtype (wt) astrocytomas formerly classified as WHO grade II or III have significantly shorter PFS and OS than IDH mutated WHO grade 2 and 3 gliomas leading to a classification as CNS WHO grade 4. It is the aim of this study to evaluate differences in the treatment-related clinical course of these tumors as they are largely unknown. Methods Patients undergoing surgery (between 2016–2019 in six neurosurgical departments) for a histologically diagnosed WHO grade 2–3 IDH1/2-wt astrocytoma were retrospectively reviewed to assess progression free survival (PFS), overall survival (OS), and prognostic factors. Results This multi-center study included 157 patients (mean age 58 years (20–87 years); with 36.9% females). The predominant histology was anaplastic astrocytoma WHO grade 3 (78.3%), followed by diffuse astrocytoma WHO grade 2 (21.7%). Gross total resection (GTR) was achieved in 37.6%, subtotal resection (STR) in 28.7%, and biopsy was performed in 33.8%. The median PFS (12.5 months) and OS (27.0 months) did not differ between WHO grades. Both, GTR and STR significantly increased PFS (P Conclusions WHO grade 2 and 3 IDH1/2 wt astrocytomas, treated according to the same treatment protocols, have a similar OS. Age, extent of resection, and strong EGFR expression were the most important treatment related prognostic factors. |
|---|---|
| ISSN: | 15737373 0167594X |
| DOI: | 10.1007/s11060-024-04585-7 |